期刊
CANCER CELL
卷 33, 期 3, 页码 386-+出版社
CELL PRESS
DOI: 10.1016/j.ccell.2018.01.012
关键词
-
资金
- NIDDK [F30DK103359-01A1, K08DK093705, R03DK109232]
- JSPS
- Agency for Science, Technology, and Research in Singapore
- NIH [R00HG008399, P01HL032262, P30DK049216]
- NHLBI [DP2OD022716]
- Burroughs Wellcome Fund
- American Society of Hematology
- JSPS [16H06391, 17H01567]
- American Cancer Society [RSG-13-379-01-LIB]
- American Society of Hematology Bridge Grant
- [15J10130]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER
- NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R00HG008399] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK049216, R03DK109232, R01DK111455, F30DK103359, K08DK093705] Funding Source: NIH RePORTER
To identify novel targets for acute myeloid leukemia (AML) therapy, we performed genome-wide CRISPR-Cas9 screening using AML cell lines, followed by a second screen in vivo. Here, we show that the mRNA decapping enzyme scavenger (DCPS) gene is essential for AML cell survival. The DCPS enzyme interacted with components of pre-mRNA metabolic pathways, including spliceosomes, as revealed by mass spectrometry. RG3039, a DCPS inhibitor originally developed to treat spinal muscular atrophy, exhibited anti-leukemic activity via inducing pre-mRNA mis-splicing. Humans harboring germline biallelic DCPS loss-of-function mutations do not exhibit aberrant hematologic phenotypes, indicating that DCPS is dispensable for human hematopoiesis. Our findings shed light on a pre-mRNA metabolic pathway and identify DCPS as a target for AML therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据